智通财经APP获悉，艾美疫苗(06660)再涨超6%，截至发稿，涨5.82%，报3.82港元，成交额580.81万港元。
消息面上，艾美疫苗发布公告，继2025年3月该疫苗获美国食品和药品监督管理局(FDA)批准开展临床试验后，集团研发的mRNA带状疱疹疫苗已于近日获得国家药品监督管理局《药物临床试验批准通知书》。该疫苗中美双报并均获批准，充分验证了集团mRNA技术平台的强劲实力。
公告指出，目前国际上尚无mRNA带状疱疹疫苗获批上市，带状疱疹疫苗在国内目标人群中接种率不到1%，存在巨大提升空间。2024年度GSK的带状疱疹疫苗全球销售额约43.10亿美元。根据行业顾问灼识咨询预测，预计到2030年，带状疱疹疫苗在中国的市场规模将达到约人民币200亿元，全球的市场规模将达到约239亿美元。该产品获批上市后，将给集团带来可观的业绩增长，艾美的mRNA带状疱疹疫苗在安全性和免疫原性上的优势，有望重塑市场格局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.